Resolution

Gemeinsamer Bundesausschuss

of the Federal Joint Committee (G-BA) on the Discontinuation of the Benefit Assessment of Ceftolozan/Tazobactam According to Section 35a SGB V

of 17 September 2020

At its session on 17 September 2020, the Federal Joint Committee (G-BA) passed the following resolution:

I. The procedure for the benefit assessment of ceftolozan/tazobactam according to Section 35a SGB V in the therapeutic indications hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults, complicated intra-abdominal infections in adults, complicated urinary tract infections in adults, and acute pyelonephritis in adults, will be discontinued.

II. Following its publication on the internet on the G-BA website, the resolution will enter into force with effect from 17 September 2020.

With the exception of the evaluation of the application in accordance with Section 35a, paragraph 1c SGB V, the justification to this resolution will be published on the website of the G-BA at www.g-ba.de .

Berlin, 17 September 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken